Navigation Links
Celebrex Appears Easier on Stomach for Arthritis Patients
Date:6/17/2010

Diclofenac plus proton pump inhibitor quadrupled risk of gastrointestinal damage, study found

THURSDAY, June 17 (HealthDay News) -- Patients who take the painkiller celecoxib for arthritis pain and inflammation are less likely to suffer gastrointestinal damage than those who take diclofenac plus omeprazole, a new study finds.

Celecoxib (Celebrex) is a cox-2 selective non-steroidal anti-inflammatory drug (NSAID), diclofenac (Voltaren) is a non-selective NSAID and omeprazole (Prilosec) is a proton pump inhibitor (PPI).

The study included 4,484 patients in 32 countries or territories who were randomly selected to receive either 200 milligrams (mg) of celecoxib twice a day (2,238 patients) or 75 mg of diclofenac slow-release plus 20 mg of omeprazole (2,246 patients) once a day.

Patients taking diclofenac plus omeprazole were more than four times more likely to suffer upper or lower gastrointestinal damage than celecoxib patients -- 3.8 percent versus 0.9 percent, respectively.

The findings, which were released online June 17 in advance of publication in a future print issue of The Lancet, should prompt a review of approaches used to reduce the risk of NSAID treatment, said the authors of the CONDOR study.

"Since guidelines recommend that selection of NSAID therapy be driven by consideration of both cardiovascular and gastrointestinal effects of treatment, CONDOR has provided new data relevant to patients requiring anti-inflammatory therapy who are at increased gastrointestinal but not increased cardiovascular risk. In this population, the gastrointestinal outcomes of a cox-2 selective NSAID were quite different to those of a non-selective NSAID plus a PPI," Francis Chan of Prince of Wales Hospital, Hong Kong Special Administrative Region, China, and Jay Goldstein of the University of Illinois at Chicago, and colleagues wrote.

"Further understanding of the cardiovascular outcomes of these two strategies requires the results of ongoing trials that have been designed directly to address that important clinical question. The findings of the CONDOR trial should encourage guideline committees to review their treatment recommendations for arthritis patients," the researchers concluded.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about arthritis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 17, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Can Celebrex prevent cancer-causing colon polyps?
2. Celebrex Might Thwart Inherited Skin Cancers
3. NAMI Medical Director Honored with APA Patient Advocacy Award; Appears in CNN Health and Huffington Post Columns
4. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
5. Hospitalization Appears to Help Personality Disorder Patients
6. How health care is paid for appears to impact outcome
7. Protein Appears Key to Intestinal Balance
8. Medication appears well-tolerated, beneficial in Huntingtons disease patients
9. Ashworth College Instructor Dr. Nicole Detling Miller Appears on Colbert Report
10. Brain Damage: NFL ‘Gets It,' American Society of Anesthesiologists Still Appears ‘Asleep'
11. Traumatic brain injuries: Motor deficits can persist even after what appears to be a full recovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex Appears Easier on Stomach for Arthritis Patients
(Date:3/24/2017)... ... ... “Finding Christ Through Social Media: Year One #A365DayJourney to ... path toward true communion with God. “Finding Christ Through Social Media: Year One ... published author Lea Michelle Johnson, a follower of Christ, wife and mother who ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: ... of God in congregations across the United States. “The Communion of Saints” ... 1964 who has served congregations in seven states throughout his long career of ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates ... based on a review of GPA and SAT/ACT requirements at 221 institutions in 25 ... argues that this higher bar should be set by states, by the Council for ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... 2017  HealthMine surveys with 9,250 insured consumers fielded ... plan members want help from their plans in five ... their health, 2) help closing gaps in care, 3) ... and 5) relevant, real-time guidance. Meeting these needs is ... A Reason to Stay Engaged ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
Breaking Medicine Technology: